Literature DB >> 29443192

Neurology and altitude illness.

Terry Rolan1.   

Abstract

Problems at altitude are most often thought of in trained athletes summiting extremes of elevation. A more common group that needs consideration is the average person with obstructive sleep apnea who must travel to high altitudes for business or pleasure. While the altitudes involved are not likely to be as extreme as for those athletes climbing peaks like Mt. Everest, the increases in elevation may present difficulties for patients, especially if overnight stay is expected. The pathophysiology of altitude-related CNS, respiratory, and sleep disorders is discussed along with treatment options.

Entities:  

Year:  2015        PMID: 29443192      PMCID: PMC5764444          DOI: 10.1212/CPJ.0000000000000100

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  34 in total

1.  Lessons learned: Operation Anaconda.

Authors:  George S Midla
Journal:  Mil Med       Date:  2004-10       Impact factor: 1.437

2.  Decrease of asymmetric dimethylarginine predicts acute mountain sickness.

Authors:  Markus Tannheimer; Kerstin Hornung; Matthias Gasche; Bernd Kuehlmuss; Matthias Mueller; Heiko Welsch; Klaus Landgraf; Christoph Guger; Roland Schmidt; Jürgen Michael Steinacker
Journal:  J Travel Med       Date:  2012-09-24       Impact factor: 8.490

3.  High-altitude pulmonary edema is initially caused by an increase in capillary pressure.

Authors:  M Maggiorini; C Mélot; S Pierre; F Pfeiffer; I Greve; C Sartori; M Lepori; M Hauser; U Scherrer; R Naeije
Journal:  Circulation       Date:  2001-04-24       Impact factor: 29.690

4.  Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial.

Authors:  Tsogyal D Latshang; Yvonne Nussbaumer-Ochsner; Rahel M Henn; Silvia Ulrich; Christian M Lo Cascio; Bruno Ledergerber; Malcolm Kohler; Konrad E Bloch
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

5.  Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT).

Authors:  Jeffrey H Gertsch; Grant S Lipman; Peter S Holck; Andrew Merritt; Allison Mulcahy; Robert S Fisher; Buddha Basnyat; Eric Allison; Keeli Hanzelka; Alberto Hazan; Zachary Meyers; Justin Odegaard; Benjamin Pook; Mark Thompson; Brant Slomovic; Henrik Wahlberg; Vanessa Wilshaw; Eric A Weiss; Ken Zafren
Journal:  Wilderness Environ Med       Date:  2010-06-16       Impact factor: 1.518

Review 6.  New insights in the pathogenesis of high-altitude pulmonary edema.

Authors:  Urs Scherrer; Emrush Rexhaj; Pierre-Yves Jayet; Yves Allemann; Claudio Sartori
Journal:  Prog Cardiovasc Dis       Date:  2010 May-Jun       Impact factor: 8.194

7.  Acetazolamide attenuates the ventilatory response to arousal in patients with obstructive sleep apnea.

Authors:  Bradley A Edwards; James G Connolly; Lisa M Campana; Scott A Sands; John A Trinder; David P White; Andrew Wellman; Atul Malhotra
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

Review 8.  Clinical consequences of altered chemoreflex control.

Authors:  Maria Plataki; Scott A Sands; Atul Malhotra
Journal:  Respir Physiol Neurobiol       Date:  2013-05-13       Impact factor: 1.931

9.  Effect of oxygen in obstructive sleep apnea: role of loop gain.

Authors:  Andrew Wellman; Atul Malhotra; Amy S Jordan; Karen E Stevenson; Shiva Gautam; David P White
Journal:  Respir Physiol Neurobiol       Date:  2008-06-03       Impact factor: 1.931

Review 10.  Frontiers of hypoxia research: acute mountain sickness.

Authors:  R C Roach; P H Hackett
Journal:  J Exp Biol       Date:  2001-09       Impact factor: 3.312

View more
  1 in total

Review 1.  The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis.

Authors:  Hsin-Ming Liu; I-Jen Chiang; Ken N Kuo; Cher-Ming Liou; Chiehfeng Chen
Journal:  Ther Adv Respir Dis       Date:  2016-11-15       Impact factor: 4.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.